Changeflow GovPing Healthcare & Life Sciences Kappa Opioid Receptor Agonist KTAC Compounds Pa...
Routine Notice Added Final

Kappa Opioid Receptor Agonist KTAC Compounds Patent Application EP4157308A2

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Detected
Email

Summary

The European Patent Office published patent application EP4157308A2 for Kappa Opioid Receptor Agonist-Therapeutic Antigen Binding Protein Conjugate (KTAC) compounds on April 15, 2026. The application, filed by Cara Therapeutics, Inc. with inventors Chalmers and Lewis, covers pharmaceutical compositions related to A61K and C07K classifications. Designated states include all EPO member states across the European Patent Convention region.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 58 changes logged to date.

What changed

The EPO published patent application EP4157308A2 covering Kappa Opioid Receptor Agonist-Therapeutic Antigen Binding Protein Conjugate (KTAC) compounds on April 15, 2026. The application is classified under multiple IPC codes including A61K 47/68, A61K 38/07, A61K 39/395, C07K 5/107, C07K 16/24, and A61K 31/50, indicating a range of pharmaceutical formulations and therapeutic applications.

Affected parties include pharmaceutical companies engaged in opioid receptor research and therapeutic protein development. Competitors in the kappa opioid receptor agonist space should review the application claims to assess potential freedom-to-operate implications for their own drug development programs.

Archived snapshot

Apr 25, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

KAPPA OPIOID RECEPTOR AGONIST-THERAPEUTIC ANTIGEN BINDING PROTEIN CONJUGATE (KTAC) COMPOUNDS

Publication EP4157308A2 Kind: A2 Apr 15, 2026

Applicants

Cara Therapeutics, Inc.

Inventors

CHALMERS, Derek, T., LEWIS, Michael, E.

IPC Classifications

A61K 47/68 20170101AFI20250425BHEP A61K 38/07 20060101ALI20250425BHEP A61K 39/395 20060101ALI20250425BHEP C07K 5/107 20060101ALI20250425BHEP C07K 16/24 20060101ALI20250425BHEP A61K 31/50 20060101ALI20250425BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Instrument
Notice
Branch
International
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application filing Drug compound research
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!